The authors argue that MPAL is not merely a diagnostic curiosity but a window into the fundamental biology of hematopoietic lineage commitment. The fifth edition of the World Health Organization classification (WHO-HEM5) and the International Consensus Classification (ICC) have refined lineage assignment criteria and genetic exclusions, yet uncertainty persists in cases with borderline myeloperoxidase expression, bilineal architecture, and treatment-associated lineage change. These borderline scenarios expose the limitations of phenotype-based classification systems that were never designed to accommodate cells straddling two developmental programs simultaneously.

Genomic and single-cell studies have revealed that similar immunophenotypes can arise from distinct clonal trajectories. Lesions such as BCR::ABL1 fusion, KMT2A rearrangements, BCL11B deregulation, and TP53 alterations shape developmental potential, prognosis, and therapeutic vulnerability in ways that immunophenotyping alone cannot capture. Two patients with identical blast surface markers may harbor fundamentally different founding clones, explaining why treatment responses can diverge so dramatically even among individuals who appear clinically comparable at diagnosis.

This clonal heterogeneity has direct therapeutic consequences. Retrospective evidence supports acute lymphoblastic leukemia-like induction for many children and fit younger adults with MPAL, whereas treatment in adults requires closer integration of age, fitness, adverse genetics, and early measurable residual disease response. The review emphasizes that MPAL management cannot rely on a single protocol; it must be adaptive, tracking the founding clone across phenotypic states through rapid genomic profiling, broad flow and molecular MRD assessment, and systematic reassessment at relapse.

The therapeutic landscape for MPAL has broadened considerably in recent years. Tyrosine kinase inhibitors targeting BCR::ABL1, venetoclax, menin inhibitors, bispecific antibodies, antibody-drug conjugates, and cellular therapies now offer multiple angles of attack. Yet these agents can also impose selective pressures that promote antigen loss or lineage switch, the very phenomena that make MPAL so difficult to eradicate. A therapy that clears blasts expressing one surface marker may simply enrich a subclone that has shed that marker or committed to the opposite lineage.

Measurable residual disease monitoring emerges as the critical connective tissue in the authors’ proposed framework. Rather than relying on a single flow cytometry gate or a single fusion transcript, MPAL management should employ broad flow and molecular MRD assessment capable of detecting the founding clone regardless of its current phenotypic costume. Early MRD response, the review argues, should inform treatment intensity decisions in adults, where the balance between aggressive induction and tolerability is most delicate.

The review also addresses treatment-associated lineage change, a phenomenon in which therapy itself drives leukemic cells to abandon their original identity. This plasticity is not random; it reflects the underlying developmental potential encoded in the founding clone’s genomic lesions. BCL11B deregulation, for instance, is associated with T-lymphoid identity, while KMT2A rearrangements can sustain both myeloid and lymphoid programs. Understanding which lesions confer which developmental potentials allows clinicians to anticipate where a clone might flee under therapeutic pressure.

The authors call for prospective international studies linking lineage architecture, genomic drivers, target distribution, and MRD kinetics to define durable treatment strategies for MPAL. Without such studies, the field remains dependent on retrospective evidence and extrapolation from ALL and AML trials, populations from which MPAL patients were often excluded precisely because of their ambiguous phenotype. The rarity of MPAL makes single-center prospective trials impractical, underscoring the need for coordinated international collaboration.

What makes this review particularly timely is the convergence of several technological advances: single-cell multiomics, broad molecular MRD platforms, and a growing arsenal of targeted agents. Together, these tools make it feasible, for the first time, to manage MPAL as a dynamic clonal disease rather than a static diagnostic category. The founding clone can be identified at diagnosis, tracked through treatment, and reassessed at relapse, with therapy adjusted in response to its evolutionary behavior.

The Tongji Hospital team’s synthesis, published open access under a Creative Commons license and funded by the National Natural Science Foundation of China, arrives as hematologists worldwide grapple with how to integrate these advances into clinical practice. For a disease that sits at the boundary of two classical categories, MPAL may ultimately prove to be the proving ground for a new paradigm in hematology: one in which lineage is not a fixed label but a moving target, and in which the founding clone, not the blast phenotype, is the true unit of disease.

Subject of Research: Mixed phenotype acute leukemia: classification, clonal biology, and precision therapy

Article Title: Mixed phenotype acute leukemia across lineage boundaries: from classification to clonal biology and precision therapy

Article References: Wang, Y., Su, S., & Xiao, Y. (2026). Mixed phenotype acute leukemia across lineage boundaries: from classification to clonal biology and precision therapy. Cancer Cell International. https://doi.org/10.1186/s12935-026-04486-x

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04486-x

Keywords: mixed phenotype acute leukemia, MPAL, acute leukemia, lineage plasticity, measurable residual disease, precision medicine, hematology, WHO-HEM5, International Consensus Classification, BCR::ABL1, KMT2A, venetoclax

Transfer RNAs have long occupied a quiet corner of molecular biology. These small RNA molecules perform one of the most essential tasks in every living cell: during mRNA translation, they read the genetic instructions carried by messenger RNA and deliver the corresponding amino acids, which are then linked together to build proteins. Because every cell needs its proteins made, tRNAs were historically viewed as housekeeping components — abundant, interchangeable, and largely indifferent to the specific fate of the cell they serve. The new research challenges that view at its foundation. “The discovery opens an entirely new realm of cancer biology that was previously unrecognized,” said Andrew Hsieh, MD, co-corresponding author of the study and a professor and associate director of Fred Hutch’s Human Biology Division. “Historically, tRNAs have been thought to play a bystander role in cell maintenance and disease, but our study shows that tRNAs can actively shape the identity of cancer cells.”

The clinical backdrop for the work is one of the most common and consequential problems in oncology. Prostate cancer is a leading cause of cancer in men, and in its early stages it is typically driven by the androgen receptor, a protein that responds to male hormones and fuels tumor growth. Because of this dependence, the androgen receptor has long been the primary target of standard prostate cancer therapies, and drugs that block its activity are often effective initially. But many tumors do not stay vulnerable. Over time, a substantial fraction of prostate cancers undergo a profound change in cellular identity, shifting to an androgen receptor-independent state in which they no longer rely on the protein that the therapies were designed to suppress. Once tumors make this transition, they become more aggressive, less responsive to treatment, and considerably harder to manage.

Understanding what drives this identity switch has been a central question in prostate cancer research. Scientists have known that genomic mutations and alterations in transcription factor-driven gene expression — changes in which genes are switched on and off — accumulate during cancer progression and can contribute to the emergence of treatment resistance. But Yeon Soo Kim, PhD, first author of the Nature paper and a postdoctoral researcher in Hsieh’s laboratory at Fred Hutch, wanted to probe a layer of regulation that had received far less attention. “We already knew that genomic mutations or transcriptional factor-dependent genetic expression are altered during the cancer progression and can lead to the development of treatment resistance,” Kim explained. “But we wanted to know more about how mRNA translation — also known as protein synthesis — is involved when the disease becomes more aggressive.” Kim’s work on the project was supported by a National Cancer Institute K99/R00 Pathway to Independence Award, a prestigious grant designed to help promising early-career scientists launch independent research careers.

Kim focused on a specific step in the translation process: the moment when a tRNA molecule reads the biological information encoded in a messenger RNA and delivers the amino acid that it carries, allowing amino acids to be joined into a growing protein chain. It is a step that happens billions of times in every cell, and it depends on a large family of tRNAs, each tuned to recognize particular codons and deliver particular amino acids. Rather than treating this machinery as uniform background noise, Kim and her colleagues asked whether individual tRNAs might be differentially deployed as prostate cancer cells change their identity — and whether those differences might matter.

To answer that question, the team assembled evidence across multiple model systems. They examined prostate cancer cell lines grown in the laboratory, mouse models of the disease, and tumor samples taken from patients. Across all of these systems, a consistent pattern emerged. A specific transfer RNA, known as tRNA1Arg(UCU), was present at high levels in androgen receptor-dependent prostate cancer cells — the treatment-sensitive state — but was markedly diminished in tumors that had become less dependent on the androgen receptor and resistant to therapy. The consistency of the pattern across cell lines, animal models and human tissue suggested that the tRNA was not an incidental byproduct of disease progression but a feature closely tied to the cancer’s state.

The most striking result came from the next set of experiments, which tested whether the correlation ran in a causal direction. When the researchers supplied the specific tRNA to treatment-resistant tumors, the tumors reverted to a state in which they were once again sensitive to therapies targeting the androgen receptor. In other words, restoring a single RNA molecule appeared to push aggressive, drug-resistant cancer cells back toward the vulnerable identity they had abandoned. “We found that we can shift the cell state between androgen receptor-dependent to an androgen receptor-independent state with a single tRNA,” Kim said. “This is important because changes in cell identity are a major reason prostate cancers become resistant to treatment. We found that this tRNA can influence whether cells remain in a drug-sensitive state or transition to one that is more aggressive.”

The implications extend well beyond the prostate. Changes in cellular identity — sometimes described as lineage plasticity — are increasingly recognized as a common route by which cancers evade targeted therapies across many tumor types. Lung cancers and breast cancers, among others, are known to undergo identity switches after treatment, allowing them to survive in forms that existing drugs no longer recognize. “In this study we used prostate cancer as an archetype to study tRNA dependent state changes, but we think it’s just the beginning,” said Kim, who plans to pursue this line of research when she establishes her own laboratory. “We can apply this approach to any type of disease models or other types of cancers that undergo identity switches after treatment, such as lung and breast cancers.” If tRNA dosage proves to be a general lever for controlling cell state, it could open a new chapter in precision oncology, one in which the translation machinery itself becomes a therapeutic target.

Kim and Hsieh are already exploring how the tRNA could be harnessed in the clinic, both as a biomarker and as a therapeutic target for aggressive prostate cancer. As a biomarker, measuring levels of tRNA1Arg(UCU) in tumor samples could potentially help clinicians determine whether a patient’s cancer remains dependent on the androgen receptor and therefore likely to respond to receptor-targeted therapies, guiding more precise treatment decisions. As a therapeutic target, the finding raises the possibility of developing interventions that restore or mimic the tRNA’s activity in resistant tumors, effectively reversing resistance rather than simply escalating treatment. Microscopy work published alongside the study illustrates the principle visually: human prostate cancer tissue with high amounts of the tRNA, revealed by dark purple and pink staining, was associated with tumors that depended on the androgen receptor for growth and were sensitive to therapies aimed at it.

The research was a collaborative effort spanning institutions. Co-corresponding author Tao Pan, PhD, of the University of Chicago brought expertise in tRNA biology to the project, and Hsieh — who holds the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch and is also a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine — contributed his laboratory’s focus on translation control in cancer. The study was funded by multiple grants from the National Institutes of Health, including the Pacific Northwest Prostate Cancer SPORE, and by the U.S. Department of Defense, with additional funding from the Prostate Cancer Foundation and the American Cancer Society. For a field that has long treated tRNAs as anonymous couriers, the message of the new work is hard to ignore: the machinery of protein synthesis may hold keys to cancer’s identity, and with them, new ways to unlock drug resistance.

Subject of Research: tRNA-mediated regulation of cell identity and drug resistance in prostate cancer

Article Title: Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance

Article References: Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, transfer RNA, tRNA1Arg(UCU), androgen receptor, drug resistance, mRNA translation, protein synthesis, cell identity, Fred Hutch Cancer Center, Nature, precision oncology, lineage plasticity

The phenomenon, known as transformed small cell lung cancer or T-SCLC, is one of the most striking examples of lineage plasticity in human cancer. Under the sustained selective pressure of EGFR-targeted therapy, tumor cells that once resembled glandular adenocarcinoma cells shed that identity and adopt the features of neuroendocrine cells, the same lineage seen in primary small cell lung cancer. Histologically, the re-biopsied tumor looks like a different disease entirely. Clinically, it behaves like one too, with rapid progression and limited treatment options. Because transformed tumors are relatively rare, they have been difficult to study systematically, and clinicians have lacked a clear biological rationale for choosing therapies after transformation occurs. The new research set out to change that by combining detailed clinical outcomes with paired genomic and transcriptomic profiling of tumors before and after transformation.

The study enrolled 32 patients whose baseline disease was pathologically confirmed as lung adenocarcinoma and who later developed transformed small cell lung cancer verified by re-biopsy after their antitumor therapy stopped working. This paired design is what gives the work its power. By analyzing specimens from the same patient at two different points in the disease course, the researchers could directly compare what changed in the tumor’s genetic and transcriptional program as it underwent lineage transformation, rather than inferring those changes from comparisons between unrelated patients. The team used next-generation sequencing to characterize genomic alterations, including single nucleotide variants and copy number alterations, and RNA sequencing to profile gene expression in both the pre-transformation EGFR-mutant adenocarcinoma and the post-transformation small cell carcinoma.

To place their findings in a broader context, the investigators also integrated publicly available gene expression data from primary small cell lung cancer, downloaded from the GEO database, allowing a three-way comparison: EGFR-mutant lung adenocarcinoma before transformation, transformed small cell lung cancer after resistance emerged, and primary small cell lung cancer arising de novo in patients without EGFR mutations. This triangulation is critical because a central clinical question has been whether transformed tumors should simply be treated like primary small cell lung cancer, or whether they retain enough of their adenocarcinoma heritage to warrant different strategies. The transcriptomic data provided a clear answer, and it is more nuanced than a simple either-or.

The researchers’ analysis of the tumor immune microenvironment revealed that transformed small cell lung cancer is markedly more immunosuppressed than the EGFR-mutant adenocarcinoma it arose from. Multiple immune regulatory pathways were downregulated after transformation, immune cell infiltration was reduced, scores of immune-related gene signatures dropped, and expression of immune checkpoint-related genes, the very molecular targets that immunotherapy drugs exploit, was diminished. In practical terms, the transformed tumor had constructed a fortress against the immune system, suppressing the inflammatory signals that normally recruit and activate anti-tumor immune cells. This finding helps explain why immune checkpoint inhibitors, which have revolutionized the treatment of many cancers, tend to perform poorly as single agents in this setting, and why the immune landscape of the transformed tumor matters so much for treatment planning.

Yet the story does not end there. When the team compared transformed small cell lung cancer with primary small cell lung cancer, they found the transformed tumors were actually more immunologically active than their de novo counterparts. Transformed tumors showed higher scores across several key immune signatures, including the MHC signature, which reflects antigen presentation machinery; the T cell-inflamed gene expression profile signature, a measure of cytotoxic T cell recruitment to the tumor; and the interferon-gamma signature, a hallmark of active immune signaling. In other words, transformed tumors sit in an intermediate immunological position: colder than the adenocarcinoma they came from, but warmer than primary small cell lung cancer. That intermediate state, the authors argue, provides a biological rationale for combining immunotherapy with chemotherapy rather than abandoning immune-based approaches altogether.

The clinical outcomes reported in the study support this reasoning. Among patients with transformed small cell lung cancer who received first-line immunotherapy plus chemotherapy, the median progression-free survival was 5.1 months and the median overall survival was 21.0 months. More strikingly, when the researchers examined treatments received after the transformed diagnosis, they found that patients who were exposed to immunotherapy at any point had a median overall survival of 21.0 months, compared with just 10.0 months for patients who never received immunotherapy, a difference that reached statistical significance with a P value of 0.03. While the retrospective design of the study means this association cannot prove causation, and selection biases may influence which patients received immunotherapy, the magnitude of the survival gap is consistent with the transcriptomic evidence that the transformed tumor microenvironment retains enough immune activity for checkpoint blockade to matter.

The technical machinery behind these conclusions deserves attention because it illustrates how modern cancer genomics translates into bedside decisions. Single-sample gene set enrichment analysis, or ssGSEA, allowed the researchers to quantify the activity of curated immune gene sets within each individual tumor sample, converting raw RNA sequencing data into interpretable immune scores. Copy number alteration and single nucleotide variant calling from next-generation sequencing confirmed the genomic continuity between the pre- and post-transformation tumors, reinforcing the understanding that transformed small cell lung cancer is not a second, independent cancer but an evolved descendant of the original adenocarcinoma, typically retaining the driver EGFR mutation even as it loses adenocarcinoma differentiation. This continuity matters clinically, because it explains why the original EGFR mutation persists in the transformed tumor even though EGFR inhibitors no longer control the disease.

For oncologists, the practical message of the study is that a diagnosis of transformed small cell lung cancer should trigger a treatment strategy informed by the tumor’s unique immune profile rather than a simple default to primary small cell lung cancer protocols. The standard first-line regimen for extensive-stage primary small cell lung cancer has long been etoposide plus platinum chemotherapy, and the addition of PD-1 or PD-L1 immune checkpoint inhibitors to this etoposide-platinum backbone has become standard practice in that disease. The new data suggest that this immunotherapy-plus-chemotherapy combination is also the most defensible first-line choice for transformed tumors, given their intermediate immune activity, and that withholding immunotherapy after transformation may cost patients a substantial survival advantage. The study also underscores the importance of re-biopsy at the time of suspected resistance, because without histological confirmation of transformation, clinicians cannot know which biological entity they are treating.

Looking forward, the research opens several avenues that could reshape the management of treatment resistance more broadly. Lineage transformation is increasingly recognized as a general mechanism of targeted therapy resistance, appearing not only in EGFR-mutant lung cancer but also in prostate cancer treated with androgen receptor inhibitors and other hormone-driven malignancies. Understanding the transcriptomic events that accompany transformation, including the downregulation of immune pathways documented here, may point to interventions that could prevent transformation before it occurs or re-invigorate the immune microenvironment after it does. The intermediate immune state of transformed tumors, colder than adenocarcinoma but warmer than primary small cell lung cancer, also raises the possibility that strategies designed to heat up cold tumors, such as combining checkpoint blockade with agents that modulate interferon signaling or antigen presentation, could further improve outcomes. For now, the study provides the most comprehensive paired portrait to date of what happens, molecule by molecule, when a lung cancer changes its identity to escape a targeted drug, and it offers patients facing that dreaded transformation a data-driven reason for cautious optimism that the right combination of therapies can still meaningfully extend their lives.

Subject of Research: Lineage transformation of EGFR-mutant lung adenocarcinoma to small cell lung cancer and its tumor immune microenvironment

Article Title: Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer

Article References: Yu, H., Li, M., Li, X., Yu, M., Pan, Y., Yun, J., & Chen, L. (2026). Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer. Journal of Translational Medicine, 24(1), Article 1123. https://doi.org/10.1186/s12967-026-08853-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08853-0

Keywords: EGFR-mutant lung cancer, small cell lung cancer transformation, lineage plasticity, tumor immune microenvironment, immunotherapy, tyrosine kinase inhibitor resistance, transcriptomics, RNA sequencing, immune checkpoint inhibitors, lung adenocarcinoma, chemoimmunotherapy, drug resistance

Prostate cancer is the archetypal lineage-dependent malignancy. Its growth hinges on the androgen receptor (AR), which is why androgen deprivation therapy and second-generation AR pathway inhibitors such as enzalutamide, apalutamide and darolutamide form the backbone of advanced disease treatment. Yet resistance is nearly universal. Tumors frequently shed their AR dependence through a process called lineage plasticity, transdifferentiating into neuroendocrine-like states that no longer respond to AR-targeted drugs. Genetic loss of TP53, PTEN or RB1 can drive this transition, but the translational mechanisms, the events at the level of protein synthesis, that permit such phenotypic flexibility have remained largely unknown.

To find them, the team performed unbiased small RNA sequencing using a multiplex platform capable of quantifying full-length tRNAs, their fragments and selected chemical modifications. They applied this technique to an engineered model in which LNCaP prostate adenocarcinoma cells were pushed into a lineage-plastic state through RB1 knockdown and overexpression of mutant TP53, MYCN, ASCL1, SRRM4, NR0B2, BCL2 and mutant KRAS. Among 49 tRNA isoacceptor families surveyed, only tRNAArg(UCU) was significantly downregulated during the transition, with a log2 fold change of roughly minus 0.34 and a false discovery rate of 2.42 x 10-25 in one analysis. Within the five tRNAArg(UCU) isodecoders, molecules sharing the same anticodon but differing in body sequence, tRNA1Arg(UCU) was the most abundant and the only one substantially decreased. Northern blotting and quantitative PCR confirmed the reduction in both LNCaP and C4-2B cells, and the decline was not accompanied by changes in tRNA fragmentation or chemical modification, indicating a specific loss of the mature molecule.

The correlation with lineage identity was striking. Across nine prostate cancer cell lines, tRNA1Arg(UCU) abundance showed a strong positive correlation with AR activity (Pearson’s r = 0.85, P = 0.0034) and a negative correlation with the neuroendocrine markers ENO2 and SCN3A. In the LTL331 patient-derived xenograft model, which transdifferentiates from adenocarcinoma to neuroendocrine prostate cancer after castration, tRNA1Arg(UCU) levels fell in a stepwise fashion from pre-castration through castration to relapse. The researchers then developed an in situ hybridization assay to visualize the tRNA directly in patient tissue. In specimens from 56 patients in the University of Washington rapid autopsy cohort, AR-positive tumors expressed significantly higher levels of tRNA1Arg(UCU) than neuroendocrine-positive tumors, and tRNA abundance correlated positively with AR activity and negatively with the neuroendocrine marker ELAVL4.

Crucially, the tRNA was not merely a passive marker. Using inducible short hairpin RNAs, the team reduced tRNA1Arg(UCU) levels by 25 to 50 percent in LNCaP and C4-2B cells. The knockdown was specific, leaving other tRNAArg(UCU) isodecoders untouched. The consequence was a coordinated shift in cell identity: AR pathway genes declined at both RNA and protein levels, while neuron-related gene programs rose. Cells depleted of the tRNA became significantly more resistant to enzalutamide, apalutamide and darolutamide, yet more sensitive to alisertib, an Aurora kinase A inhibitor with activity in neuroendocrine prostate cancer. In mice, the team generated animals haploinsufficient for n-Trtct2, the gene encoding tRNA1Arg(UCU), crossed onto the MYC-driven Hi-Myc prostate cancer model. Organoids derived from these mice showed a threefold increase in resistance to AR inhibition, and after surgical castration, haploinsufficient mice developed significantly enlarged prostates, with 25 percent exhibiting high-grade prostatic intraepithelial neoplasia compared with none of the controls.

Most remarkably, the process proved reversible. Re-expressing tRNA1Arg(UCU) in lineage-plastic cells restored AR pathway gene expression, suppressed neuroendocrine markers and resensitized the cells to AR-targeted therapies. Overexpression of other arginine tRNA isodecoders or isoacceptors had no such effect, underscoring the exquisite specificity of this single molecule. In LNCaP-abl cells, a subline that spontaneously evolved androgen insensitivity after prolonged culture in androgen-depleted medium, restoring tRNA1Arg(UCU) enhanced AR signaling and improved enzalutamide sensitivity. In the TRAMP transgenic mouse model, which normally progresses toward neuroendocrine tumors, crossing in a tRNA1Arg(UCU) overexpression allele reduced the incidence of premalignant glands after castration. Together, these experiments demonstrate that lineage dependency in prostate cancer can be toggled by modulating one tRNA species.

The team then asked how tRNA1Arg(UCU) is regulated. Mining the ENCODE database of transcription factor binding, they identified 11 DNA-binding proteins that occupy the TRR-TCT1-1 genomic locus encoding the tRNA. Four of these were downregulated during lineage transition, and functional screening pinpointed two: TARDBP, a DNA- and RNA-binding protein best known for its role in amyotrophic lateral sclerosis, and ZSCAN29, a zinc-finger protein. Silencing either factor reduced tRNA1Arg(UCU) expression, and their occupancy, measured by CUT&RUN profiling, declined selectively at the TRR-TCT1-1 locus during lineage plasticity. The locus carried the highest enrichment of the H3K4me3 histone mark among all six TRR-TCT isodecoder genes, and this mark, along with RNA polymerase III occupancy, was lost specifically at TRR-TCT1-1 during the lineage switch. TARDBP and ZSCAN29 appear to maintain RNA polymerase III recruitment at this chromatin-primed locus, and their expression correlated with tRNA1Arg(UCU) levels in patient specimens. This work provides one of the first demonstrations of isodecoder-specific transcriptional control of tRNA genes in cancer, extending tRNA regulation beyond canonical RNA polymerase III mechanics.

How does a single tRNA change cell fate? The answer lies in codon optimality. tRNA1Arg(UCU) decodes the AGA arginine codon, and the researchers built fluorescent reporters to show that translational capacity at AGA codons dropped roughly fourfold in lineage-plastic cells and was restored by tRNA addback. Polysome RNA sequencing, which separates ribosome-bound messenger RNAs by density to measure translation efficiency genome-wide, revealed that AGA codons were enriched among efficiently translated transcripts in adenocarcinoma cells, lost that enrichment in lineage-plastic cells, and regained it upon tRNA restoration. Among the translationally upregulated targets were five components of the SWI/SNF chromatin remodeling complex, and the team focused on SMARCC2, whose protein levels fell during lineage transition despite unchanged mRNA. A codon-switching experiment confirmed the mechanism: replacing SMARCC2’s AGA codons with synonymous CGC codons rendered the protein insensitive to lineage state. Silencing SMARCC2 in tRNA-restored cells reversed the AR pathway reactivation and restored enzalutamide resistance, establishing SMARCC2 as a key translational mediator through which tRNA1Arg(UCU) sustains lineage fidelity.

The clinical implications are substantial. In the rapid autopsy cohort, patients with the lowest tRNA1Arg(UCU) abundance had significantly shorter time to first bone metastasis, shorter survival after starting androgen deprivation therapy, shorter survival after developing androgen independence, and shorter overall survival overall. In mouse models, tRNA depletion led to a fourfold increase in metastatic burden following intracardiac injection of luciferase-labeled cells. The authors caution that the clinical associations are retrospective and that prospective studies will be needed to validate tRNA isodecoders as biomarkers of AR-targeted therapy resistance. But the therapeutic horizon is already visible: adeno-associated virus delivery of suppressor tRNAs has restored protein function in models of mucopolysaccharidosis type I, and lipid nanoparticle-based tRNA delivery has re-expressed CFTR in cystic fibrosis epithelia. Such platforms could, in principle, be adapted to restore tumor-suppressive tRNAs like tRNA1Arg(UCU), reprogramming lineage dependency and resensitizing tumors to existing therapies. For a disease in which treatment resistance remains the central clinical challenge, the idea that a single RNA adaptor molecule holds a master key to cellular identity is a genuinely paradigm-shifting proposition.

Subject of Research: Regulation of prostate cancer lineage plasticity and therapy resistance by tRNA dosage

Article Title: tRNA dosage regulates lineage dependency and resistance in prostate cancer

Article References: Kim, Y. S., Arora, S., Young, D., Tsou, A., Shiuan, A., Wladyka, C. L., Rudoy, D., Kim, J. Y., Waters, J. A., Schuster, S. L., Coleman, I. M., Kapur, M., Sobczyk, M., Katanski, C. D., Bayat Tork, A. M., Zhang, W., Nelson, P. S., Ha, G., Haffner, M. C., … Hsieh, A. C. (2026). tRNA dosage regulates lineage dependency and resistance in prostate cancer. Nature. https://doi.org/10.1038/s41586-026-11153-8

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11153-8

Keywords: prostate cancer, transfer RNA, lineage plasticity, androgen receptor, therapy resistance, neuroendocrine prostate cancer, translation, SMARCC2, TARDBP, ZSCAN29, RNA polymerase III, codon optimality

Cell plasticity is not a cancer-specific invention. In healthy adult tissues, cells retain a degree of flexibility that supports regeneration and repair. Under injury or environmental stress, differentiated cells can dedifferentiate into progenitor-like states, transdifferentiate into other lineages or reawaken developmental programs. Cellular identity is constrained by lineage-specific regulatory networks, but it is not permanently fixed. What cancer does is hijack these normally adaptive programs. Tumor cells exploit dedifferentiation, transdifferentiation, epithelial-mesenchymal transition and stem cell-like reprogramming to adapt to hostile microenvironments and therapeutic pressure, generating a form of intratumoral diversity that genetic mutations alone cannot explain.

The review situates plasticity alongside, rather than in opposition to, classical models of clonal evolution. Genetic alterations, including mutations in tumor suppressors and developmental regulators such as TP53, RB1, APC and KRAS, establish a permissive background by disrupting lineage constraints. Yet mutations are often insufficient to account for the rapid, reversible phenotypic changes observed under treatment. Instead, epigenetic remodeling through DNA methylation, histone modifications and chromatin accessibility changes enables dynamic state transitions without altering the underlying DNA sequence. These mechanisms are particularly important for establishing drug-tolerant states and promoting lineage reprogramming, allowing cells to survive chemotherapy, targeted therapy and immunotherapy and then resume proliferation once the pressure subsides.

Some of the most vivid examples come from lineage switching. In EGFR-mutant lung adenocarcinoma, targeted therapy can drive transformation into small-cell lung cancer-like states marked by neuroendocrine features, loss of lineage fidelity and aggressive behavior. In prostate cancer, treatment with androgen receptor-targeted therapies can push tumors toward AR-low or AR-null neuroendocrine prostate cancer, an extreme form of lineage plasticity linked to RB1 loss, activation of neural transcriptional programs such as ASCL1 and epigenetic reprogramming mediated by EZH2. Melanoma cells shift between differentiated MITF-high states and dedifferentiated, invasive AXL-high states, with the latter showing increased resistance to both targeted therapy and immune checkpoint blockade. In glioblastoma, radiation stress drives a proneural-to-mesenchymal transition involving STAT3, C/EBP-beta and NF-kappa-B signaling that is strongly associated with recurrence and poor prognosis.

The mechanisms underlying these transitions form an interconnected regulatory web. Conserved developmental signaling pathways, including TGF-beta, Wnt/beta-catenin and Notch, act as master conductors of epithelial-mesenchymal transition, stemness and differentiation. Transcription factors such as SNAIL, ZEB and TWIST repress epithelial genes while activating mesenchymal programs, and lineage-defining factors from the SOX and KLF families regulate stem-like states. Remarkably, even the cell’s physical architecture participates: loss of CRACD, a regulator of actin dynamics, disrupts the cytoskeleton and triggers neuroendocrine plasticity by suppressing YAP-NOTCH signaling while driving EZH2-dependent chromatin remodeling that represses antigen-presentation pathways and facilitates immune evasion. Noncoding RNAs add another layer, with the miR-200 family forming a feedback loop with ZEB factors that controls the balance between epithelial and mesenchymal states.

The tumor microenvironment acts as an external choreographer of plasticity. Hypoxia stabilizes hypoxia-inducible factors that activate programs of stemness, metabolic reprogramming and EMT, enriching invasive cell populations within oxygen-starved niches. Tumor-associated macrophages secrete TGF-beta, IL-6 and TNF-alpha, reinforcing EMT and immune evasion. Cancer-associated fibroblasts deposit and remodel extracellular matrix, increasing tissue stiffness and activating mechanotransduction pathways such as integrin-FAK-Src and YAP/TAZ that induce EMT and invasion. Endothelial cells contribute angiocrine signals, including Notch ligands and IL-6, that maintain cancer stem cell phenotypes. The extracellular matrix itself is not a passive scaffold but an active regulator whose composition and mechanics drive phenotypic switching and metastatic potential.

Plasticity also shapes how tumors begin. In the intestine, activation of NF-kappa-B signaling can cooperate with Wnt pathway activation to induce dedifferentiation of non-stem epithelial cells into tumor-initiating cells, expanding the pool of cells capable of starting a tumor. During colonic injury, epithelial cells undergo YAP/TAZ-dependent reprogramming toward a fetal-like regenerative state that is normally transient and repair-oriented. But when oncogenic alterations such as APC loss or KRAS activation are present, these regenerative programs can become aberrantly stabilized, supporting neoplastic transformation. In the pancreas, chronic inflammation promotes acinar-to-ductal metaplasia, and persistent inflammation combined with oncogenic KRAS drives progression toward pancreatic ductal adenocarcinoma. Tumor initiation, the review argues, is determined not only by the cell of origin but by the plastic potential of the transformed cell and its microenvironmental context.

Metastasis, too, is increasingly understood as a plasticity-driven performance rather than the work of a fixed population of metastatic cells. During invasion, epithelial tumor cells acquire partial or mesenchymal traits that enhance motility, and hybrid epithelial-mesenchymal states, which retain both migratory and proliferative capacities, confer greater metastatic potential than fully mesenchymal states. Circulating tumor cells in hybrid states survive shear stress and oxidative damage more effectively, and clustered circulating cells show even greater metastatic efficiency. Upon reaching distant organs, many cells must reverse the process through mesenchymal-epithelial transition to regain proliferative capacity and colonize new tissue. A subset of disseminated cells enters dormant, drug-resistant states and can later reactivate, producing metastatic relapse years after clinical remission.

Therapy resistance is where plasticity exacts its greatest clinical toll. Rather than relying on the slow selection of pre-existing mutations, tumor cells can adopt transient drug-tolerant persister states characterized by reduced proliferation, altered metabolism and activated stress-response pathways. These cells harbor no stable resistance-conferring mutations, yet they survive treatment and reenter the cell cycle upon drug withdrawal, giving rise to relapse. Epigenetic reprogramming underpins this reversibility, and the review highlights emerging therapeutic strategies that target it directly. EZH2 inhibition can reverse lineage-infidelity programs in treatment-resistant prostate cancer models and restore sensitivity to androgen receptor-directed therapy. LSD1 inhibition can suppress ASCL1-dependent neuroendocrine plasticity in small-cell lung cancer and restore TP53 signaling in neuroendocrine prostate cancer, while BET protein inhibition blocks treatment-emergent neuroendocrine lineage programs. Because these regulators can have context-dependent effects on cell identity, the authors emphasize that biomarker-guided combinations and careful therapeutic timing will be essential.

Perhaps the most transformative development is technological. Single-cell RNA sequencing has revealed that cancer cells occupy a continuum of transcriptional states rather than discrete fixed identities, exposing rare transitional populations that bulk profiling obscures. But snapshots cannot distinguish interconverting states from independent subclones, which has motivated lineage-recording technologies such as KP-Tracer and iTracer, in which CRISPR-Cas9-mediated barcode editing generates heritable scars that reconstruct clonal history alongside transcriptional profiles. Spatial transcriptomics then restores the anatomical context, revealing that tumor cell heterogeneity is organized across structured tumor regions and linking plastic states to specific microenvironmental niches, with computational tools such as cell2location and RCTD projecting single-cell states onto intact tissue maps. Framed through Waddington’s classical landscape, in which cells roll across valleys of stable identity, plasticity emerges not as a loss of differentiation but as regulated movement between alternative states. The integrated picture is one of cancer as a dynamically adaptive system, and the authors argue that pharmacological strategies designed to block maladaptive state transitions, eliminate drug-tolerant and dormant populations and disrupt the microenvironmental signals sustaining adaptability may offer a path toward preventing metastasis and achieving more durable clinical responses.

Subject of Research: Cancer cell plasticity and its role in tumor progression, metastasis and therapy resistance

Article Title: Cell plasticity in cancer and therapy resistance

Article References: Seo, Y., Jang, J., & Park, J.-I. (2026). Cell plasticity in cancer and therapy resistance. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01869-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01869-y

Keywords: cancer cell plasticity, therapy resistance, epithelial-mesenchymal transition, lineage plasticity, epigenetic reprogramming, tumor microenvironment, drug-tolerant persister cells, single-cell transcriptomics, spatial transcriptomics, cancer stem cells, metastasis, Waddington landscape

The significance of the finding lies in the sheer scale of the problem it addresses. Roughly a quarter of all lung adenocarcinomas carry mutations in the KRAS gene, a well-known oncogene that drives uncontrolled cell proliferation by locking cellular growth circuits into the on position. After decades in which KRAS was considered undruggable, the United States Food and Drug Administration has in recent years approved two inhibitors that specifically target a common mutation known as KRAS-G12C. These drugs represented a genuine milestone for patients whose tumors had stopped responding to other treatments, and they can produce meaningful initial responses. Yet the clinical experience has been sobering: while the inhibitors work in about 35 percent of the patients who receive them, tumors almost invariably develop resistance, and most cases eventually relapse.

Until now, the dominant explanation for that resistance has been genetic. Tumor cells typically reactivate KRAS signaling through secondary mutations that prevent the drug from binding to its target, or by producing additional copies of the KRAS gene so that the sheer abundance of the protein overwhelms the inhibitor. Both routes converge on the same destination: sustained activity of the MAP kinase signaling pathway, the growth-promoting cascade that KRAS normally triggers and that fuels cell division. A 2021 study from researchers at Dana-Farber Cancer Institute, which analyzed tumors from 17 patients with non-small cell lung cancer treated with KRAS-G12C inhibition, identified such secondary resistance mutations in a majority of the patients examined. But that study also contained a puzzle. In two of the patients, the tumors showed no obvious resistance mutations at all. Instead, they had transformed from adenocarcinomas into squamous cell carcinomas, a completely different class of lung tumor.

That observation is more remarkable than it might first appear. Adenocarcinomas and squamous cell carcinomas are both classified as non-small cell lung cancers, the most common form of primary lung cancer, but they are thought to arise from different cells of origin and carry distinct genetic profiles. Adenocarcinomas, the most prevalent subtype, often originate from the surfactant-producing cells that line the lungs, while squamous cell carcinomas arise from the cells lining the central airways. Critically, KRAS mutations are found far more frequently in adenocarcinomas than in squamous cell carcinomas. A tumor that abandons its adenocarcinoma identity for a squamous one is, in effect, walking away from the very dependency that the drug was designed to exploit.

To understand how such a transformation could occur, the MIT team, led by graduate student Carrie Rodriguez and Nicolas Mathey-Andrews PhD ’25, with Professor Tyler Jacks of the Koch Institute for Integrative Cancer Research as senior author, engineered a mouse model of lung cancer carrying the precise mutation targeted by the approved inhibitors. When the researchers treated these mice with a KRAS-G12C inhibitor, they found that tumors which had lost the function of a gene called Nkx2-1 were able to undergo the transition from adenocarcinoma to squamous cell carcinoma. Nkx2-1 normally helps maintain alveolar epithelial identity, acting as a guardian of the lung lineage; when it is lost, the cells appear freed from their original identity and can drift toward an alternative fate.

The researchers also identified a second route into the same destination. Turning on a transcription factor called DeltaNp63, which is overactive in many squamous cell carcinomas, made the adeno-to-squamous transition more likely. A third player, the transcription factor SOX2, also helped stimulate the transition, although it could not initiate the process on its own. Together, these findings sketch a regulatory landscape in which the fate of a lung tumor cell is governed by a balance of lineage-defining factors: loss of the lung identity keeper Nkx2-1 on one side, or overexpression of squamous master regulators such as SOX2 or DeltaNp63 on the other, can tip the cell into a new state.

What makes these transformed tumors so dangerous is what the researchers observed about their signaling. The tumors that underwent the tissue transformation did not acquire the mutations that typically boost KRAS expression in adenocarcinomas. Instead, KRAS signaling was shut off, or at least dampened significantly, rendering the inhibitor irrelevant. The cells no longer require the oncogene the drug was blocking, and the team hypothesizes that they switch on alternative signaling pathways that allow them to keep growing. Identifying those pathways is now a central goal of the ongoing work, because they could reveal targets for new drugs capable of preventing or delaying resistance to KRAS inhibitors.

The clinical implications are considerable. Targeted cancer therapies have transformed outcomes in many tumor types, but their Achilles heel has always been the emergence of resistance, and this study adds an important dimension to how that resistance can arise. If a tumor can escape a drug not by mutating the target but by changing what it fundamentally is, then combination strategies may need to account for lineage plasticity as well as classic genetic escape routes. As Rodriguez notes, the main takeaway is that there appear to be different routes of resistance to KRAS inhibitors, and the field needs to think about how to address them. Monitoring tumors for signs of transformation, and developing agents that block the transition itself, could become essential components of future treatment regimens for the many patients whose lung adenocarcinomas harbor KRAS mutations.

There is also a broader scientific payoff. As Mathey-Andrews points out, the adeno-to-squamous transition is a process that remains poorly understood, and the team was encouraged that their models could capture it in the laboratory. The researchers are now digging deeper into what happens inside tumor cells as they shift into a squamous state, hoping to uncover vulnerabilities that could be exploited therapeutically. Future work aimed at translation will use these models to define the conditions under which histologic transformation occurs and to nominate potential downstream targets for drug development. The study was supported in part by the Koch Institute Support Grant from the National Cancer Institute, a Ruth Kirschstein National Service Research Award, the National Institute of General Medical Sciences, and the Ludwig Center at MIT. For patients facing the prospect of relapse after KRAS-targeted therapy, the study offers both a warning and a roadmap: the escape routes are more varied than once believed, but they are now, for the first time, being mapped.

Subject of Research: Mechanisms of resistance to KRAS inhibitors in lung adenocarcinoma through gene amplification and lineage transformation

Article Title: Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs

Article References: Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: KRAS inhibitors, lung adenocarcinoma, squamous cell carcinoma, drug resistance, lineage plasticity, Nkx2-1, DeltaNp63, SOX2, MAP kinase pathway, KRAS-G12C, targeted therapy, Nature Genetics

The patient’s clinical journey began in January 2021, when he presented to an outpatient clinic with urinary frequency and progressive difficulty urinating. His initial serum total PSA measured 5.22 micrograms per liter, only modestly above the conventional 4 microgram-per-liter threshold that typically triggers concern. Magnetic resonance imaging revealed abnormal lesions in the peripheral zone of both sides of the prostate, and transrectal biopsy confirmed the suspicion: prostate adenocarcinoma with a Gleason score of 9 (4+5), one of the most aggressive grades assigned to this disease. The clinical stage was classified as T3aN0M0, indicating locally advanced disease that had not yet spread to lymph nodes or distant organs. Because of COVID-19 pandemic disruptions, radical surgery was postponed, and the patient instead began combined androgen blockade using bicalutamide and goserelin, a hormonal regimen designed to starve the cancer of the testosterone it craves.

Two years later, in February 2023, the patient was admitted with worsening urinary symptoms. Repeat MRI showed an enlarged prostate with lesions essentially unchanged from prior imaging, and a bone density scan detected no abnormalities. After a multidisciplinary team evaluation, he underwent laparoscopic radical prostatectomy in March 2023 without complications. Postoperative pathology reconfirmed the high-grade adenocarcinoma, and endocrine therapy with bicalutamide and goserelin continued. By June 2023, follow-up labs showed the total PSA had fallen to 0.86 micrograms per liter, while serum testosterone was undetectable. On paper, everything suggested the treatment was working: the primary tumor had been removed, hormonal therapy had chemically castrated the patient, and the biomarker that defines prostate cancer activity had collapsed to near-baseline levels.

Then, in August 2023, the picture shattered. The patient noticed a soybean-sized mass on his penis, accompanied by urinary frequency, urgency, painful urination, and five to six nighttime bathroom trips. Physical examination revealed a firm mass roughly three centimeters long within the penile corpus cavernosum, the spongy erectile tissue. Doppler ultrasonography identified a solid lesion measuring 26 by 16 by 11 millimeters in the left corpus cavernosum, suspicious for malignancy. MRI confirmed a solid mass with a high probability of metastatic tumor. Critically, his serum PSA at that moment was just 2.58 micrograms per liter, well within a range many clinicians would consider reassuring. He underwent resection of the penile lesion on August 24, 2023, and histopathology revealed poorly differentiated adenocarcinoma with intravascular tumor thrombus, evidence that cancer cells had already invaded blood vessels.

Immunohistochemical staining settled the question of origin. The tumor cells showed diffuse positive expression of androgen receptor, PSA, and P504s, also known as alpha-methylacyl-CoA racemase, a molecular fingerprint characteristic of prostate adenocarcinoma. The diagnosis was confirmed: penile metastasis from prostate cancer, an event with an estimated incidence of only 0.3 to 0.5 percent among prostate cancer patients. By October 2023, the disease had exploded. MRI detected multiple masses in both corpora cavernosa, the right ischium, and the left pubic ramus. Contrast-enhanced CT revealed scattered solid nodules in both lungs, a lesion in the right lobe of the thyroid, and multiple growing liver metastases, the largest measuring about 20 millimeters. His PSA had climbed to 13.39 micrograms per liter, and the team concluded he had relapsed with castration-resistant disease.

The authors place this case within a broader biological framework that may explain the paradox of metastasis without high PSA. In metastatic castration-resistant prostate cancer, low PSA levels often signal neuroendocrine differentiation, a process in which tumor cells undergo what researchers call lineage plasticity. Under the selective pressure of continuous hormonal therapy, adenocarcinoma cells accumulate genomic alterations such as RB1 and TP53 mutations and epigenomic changes including DNA methylation and EZH2 overexpression. The splicing regulator SRRM4 induces alternative splicing that produces a non-functional variant of the neuronal repressor REST, while upregulation of N-MYC, PEG10, and transcription factors like BRN2, SOX2, and SOX11 grants the cells stem-like and neuron-like properties. The cells shift toward a mesenchymal state, marked by elevated vimentin and SNAIL, suppressed androgen receptor signaling and its downstream genes including PSA, and increased neuroendocrine markers such as synaptophysin, chromogranin A, and neuron-specific enolase. The result is a tumor that proliferates aggressively but no longer manufactures the very protein clinicians use to track it.

The authors acknowledge an important limitation: their penile tumor specimen was not stained for neuroendocrine markers, so the evidence for this mechanism in the present case remains indirect. Still, the anatomical route of spread is clearer. Roughly 75 percent of metastatic penile cancer originates from adjacent genitourinary and pelvic organs, chiefly the bladder at 28.6 percent and the prostate at 27.9 percent. About 90 percent of secondary penile tumors disseminate through veins and lymphatics, with the remainder arriving via direct extension or iatrogenic implantation. In this patient, retrograde venous or lymphatic dissemination is the most likely mechanism, supported by the locally advanced initial stage, the intravascular tumor thrombus seen on histopathology, the corpus cavernosum involvement, and the rapid systemic dissemination that followed.

The clinical trajectory after the penile diagnosis was relentless. In November 2023, PSA reached 32.5 micrograms per liter and PET-CT identified extensive systemic metastases. By January 2024, the patient required a suprapubic cystostomy to manage urinary obstruction, and PSA had risen to 39.60 micrograms per liter. Treatment escalated through abiraterone and then enzalutamide, but by April 2024 PSA had surged to 253.01 micrograms per liter, and by late June it hit 577.47. Testosterone remained below detection, confirming that the cancer no longer depended on androgens. Laboratory values painted a picture of systemic decline: low potassium, low albumin, anemia with hemoglobin of 91 grams per liter, and elevated inflammatory markers including C-reactive protein at 71.38 milligrams per liter. Androgen deprivation therapy offered no benefit, so the team transitioned to metronomic therapy with opioid pain control. The patient died in August 2024, 43 months after his initial diagnosis and just 12 months after the penile metastasis was detected.

Survival statistics for this rare complication are grim across the literature. A 2006 review by Cherian and colleagues collected 372 cases of secondary penile tumors, 125 of them from prostate cancer, and found most patients died within a year of presentation. A 2023 update by Landen and colleagues added 72 new cases documented between 2006 and 2021, reporting a median cancer-specific survival of 14.3 months for prostate primaries. Approximately 41 percent of patients with prostate-derived penile metastasis die within six months of diagnosis, and those who develop malignant priapism fare even worse. Metastasis-directed therapies such as surgical excision, radiotherapy, and stereotactic body radiation can achieve favorable local PSA responses and relieve symptoms, but no study has demonstrated a meaningful overall survival benefit. For patients whose low PSA reflects neuroendocrine differentiation, current guidance suggests prioritizing chemotherapy with agents like docetaxel or cabazitaxel, platinum-based regimens, or emerging targeted therapies rather than continuing androgen deprivation alone.

The takeaway from this case is a call for diagnostic humility. The authors recommend that any patient presenting with penile complaints and a history of prostate malignancy should be suspected of harboring penile metastasis, even when bone disease appears controlled and PSA sits in the low range under hormonal therapy. Patients with high-grade, locally advanced prostate cancer and atypical features deserve heightened vigilance. Beyond conventional PSA testing, the report advocates complete physical examination, imaging with MRI or, preferably, gallium-68 PSMA PET/CT, the most sensitive modality for detecting prostate cancer metastasis, and additional serum biomarkers. Notably, this patient never received PSMA PET/CT because it was not part of routine workup at the treating institution, and the authors concede its absence may have allowed additional metastatic lesions to escape detection. As prostate cancer treatment extends survival for millions worldwide, this case stands as a vivid reminder that the disease can rewrite its own molecular identity, slipping beneath the biomarker radar precisely when clinicians feel most confident it has been defeated.

Subject of Research: Penile metastasis of prostate cancer occurring with low serum PSA levels

Article Title: Prostate cancer metastasis to the penis with low serum prostate specific antigen level: A case report

Article References: Wang, Z., Lai, Y., Wu, H., Zhang, J., Liang, H., & Wang, X. (2026). Prostate cancer metastasis to the penis with low serum prostate specific antigen level: A case report. Heliyon, 12(15), Article e45456. https://doi.org/10.1016/j.heliyon.2026.e45456

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45456

Keywords: prostate cancer, penile metastasis, PSA, castration-resistant prostate cancer, neuroendocrine differentiation, androgen deprivation therapy, PSMA PET/CT, case report, lineage plasticity, immunohistochemistry, Gleason score, Heliyon

Claudin-1, or CLDN1, has long been defined by its day job. It is a tight junction protein, a structural component that seals the gaps between epithelial cells, controlling what passes through tissue barriers and holding cellular sheets together. In cancer research, CLDN1 has mostly been studied in that architectural context, with its dysregulation implicated in tumor progression and metastasis across multiple cancer types. But the new work, led by researchers at Nanjing Medical University and collaborating institutions in China, demonstrates that CLDN1 has a second, hidden life inside the cell. Far from the cell membrane’s junctions, the protein operates deep within the endoplasmic reticulum, the organelle responsible for folding and quality-controlling the proteins that cells need to survive.

The endoplasmic reticulum is an unforgiving workplace. When protein folding demands exceed the organelle’s capacity, misfolded proteins accumulate and trigger a condition called endoplasmic reticulum stress. If the stress is mild, the cell activates adaptive signaling pathways that expand folding capacity and restore balance. If the stress is severe or prolonged, the same machinery flips into a destructive mode, executing a form of programmed cell death designed to eliminate damaged cells. Chemotherapy drugs such as docetaxel impose exactly this kind of burden, overwhelming the folding machinery and pushing cancer cells toward the lethal threshold. The researchers reasoned that tumors which survive this assault must have found ways to buffer the stress, and their search for those buffers led them directly to CLDN1.

To identify the key regulators of neuroendocrine differentiation and docetaxel resistance, the team integrated transcriptome data from multiple public cohorts with their own RNA sequencing of prostate cancer models. This multi-cohort analysis pinpointed CLDN1 as a consistent feature of both neuroendocrine prostate cancer and chemotherapy-resistant tumors. The correlation was striking: in clinical tissue specimens from human prostate cancer patients, CLDN1 expression showed a significant positive relationship with established neuroendocrine markers such as neuron-specific enolase and synaptophysin. In other words, the tumors that expressed the most CLDN1 were the ones most likely to display the neuroendocrine signature that portends aggressive, treatment-resistant disease.

Having established the clinical association, the researchers moved into mechanistic territory. Using co-immunoprecipitation coupled with mass spectrometry, they mapped the proteins that physically associate with CLDN1 and discovered that it interacts with two critical players in endoplasmic reticulum biology. The first is USP7, a deubiquitinase enzyme that removes ubiquitin tags from target proteins. Ubiquitin attachment is the cell’s universal signal for destruction, so deubiquitinases act as molecular rescuers, pulling proteins back from the degradation pathway. The second player is calnexin, or CANX, a chaperone protein embedded in the endoplasmic reticulum membrane that helps newly synthesized proteins fold correctly and directs misfolded ones toward degradation.

The experiments revealed a precise biochemical sequence. CLDN1 promotes the recruitment of USP7 to the endoplasmic reticulum membrane, where USP7 removes ubiquitin molecules from calnexin at three specific conserved lysine residues, numbered K118, K170, and K199. The team confirmed this site specificity through ubiquitination assays and site-directed mutagenesis, showing that altering these lysines abolished the protective effect. With its ubiquitin tags removed, calnexin is stabilized, and the endoplasmic reticulum gains a larger and more durable folding workforce. Transmission electron microscopy provided visual confirmation of the cellular consequences, revealing that CLDN1-high cells maintained endoplasmic reticulum structure under conditions that would otherwise damage the organelle. The practical result is that chemotherapy-induced stress, which should push these cells over the lethal threshold, is instead absorbed and neutralized.

The functional consequences of this buffering system extend beyond simple survival. Using gain- and loss-of-function approaches in prostate cancer cell lines, the researchers showed that CLDN1 drives neuroendocrine transdifferentiation, pushing cells toward the lineage-plastic state that characterizes treatment-resistant disease. Conversely, depleting CLDN1 undermined both the neuroendocrine shift and resistance to docetaxel. The team validated these findings in vivo using subcutaneous xenograft models in mice, where manipulating CLDN1 levels changed how tumors responded to chemotherapy. The picture that emerges is of a single protein coordinating two of the most feared features of advanced prostate cancer: the identity change that escapes targeted therapies and the stress tolerance that escapes cytotoxic drugs.

Perhaps the most therapeutically exciting finding came when the researchers deliberately reversed the process. Tunicamycin, a pharmacological agent that blocks a key step in protein glycosylation and thereby activates endoplasmic reticulum stress, effectively reversed CLDN1-induced neuroendocrine differentiation and chemoresistance in the animal models. In essence, re-imposing the stress that CLDN1 had learned to buffer stripped the tumors of their adaptive advantage. This proof-of-concept experiment suggests that the endoplasmic reticulum stress response is not merely a bystander in treatment resistance but an actionable vulnerability. If clinicians could pharmacologically tip the stress balance in the lethal direction at the right moment, they might prevent or reverse the lineage plasticity that makes neuroendocrine prostate cancer so difficult to treat.

The study also expands the conceptual framework of cancer biology in a broader sense. Tight junction proteins have traditionally been studied as structural elements, and organelle homeostasis has traditionally been studied through dedicated stress-response pathways. The CLDN1-USP7-CANX axis demonstrates that these worlds intersect, with a junctional protein moonlighting as a regulator of deubiquitinase recruitment and chaperone stability deep inside the cell. This noncanonical function provides a molecular link between cell architecture, protein quality control, and tumor cell reprogramming, and it raises the question of whether other tight junction proteins harbor similar hidden roles in organelle biology. The finding also adds to a growing appreciation that post-translational modifications, particularly site-specific deubiquitination, can serve as master switches controlling how cancer cells respond to therapeutic pressure.

For patients with advanced prostate cancer, the clinical stakes are considerable. Neuroendocrine prostate cancer typically emerges after years of androgen receptor-targeted treatment, and once it appears, prognosis is poor because neither hormonal manipulation nor standard chemotherapy works reliably. The identification of the CLDN1-USP7-CANX pathway offers several potential intervention points: blocking the CLDN1-USP7 interaction, inhibiting USP7 recruitment to the endoplasmic reticulum, or pharmacologically exploiting the stress vulnerability that CLDN1 normally shields. USP7 inhibitors already exist in early clinical development for other indications, which could accelerate translational efforts. The work was supported by the National Natural Science Foundation of China and the Jiangsu Provincial Health Commission, and the corresponding authors include Lei Yang, Haoli Yin, and Qingyi Zhu. While the road from mechanism to medicine is long, this study provides a clear molecular target for a disease state that has stubbornly resisted every previous attempt at rational attack, and it demonstrates that sometimes the most important discoveries about a well-known protein are found in the places no one thought to look.

Subject of Research: The role of Claudin-1 in endoplasmic reticulum stress regulation, lineage plasticity, and chemoresistance in prostate cancer

Article Title: Noncanonical function of Claudin-1 mitigates lethal endoplasmic reticulum stress to drive prostate cancer lineage plasticity and chemoresistance

Article References: Li, Y., Li, Y., Li, S., Li, K., Dong, Y., Chen, Z., Zhou, K., Ji, Z., Yang, L., Yin, H., & Zhu, Q. (2026). Noncanonical function of Claudin-1 mitigates lethal endoplasmic reticulum stress to drive prostate cancer lineage plasticity and chemoresistance. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06430-8

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06430-8

Keywords: prostate cancer, Claudin-1, neuroendocrine prostate cancer, endoplasmic reticulum stress, lineage plasticity, chemoresistance, docetaxel, USP7, calnexin, deubiquitination, castration-resistant prostate cancer, tumor reprogramming

The research team turned to genetically engineered mouse models of Kras-driven lung adenocarcinoma, the workhorse systems that have long defined lung cancer biology. These autochthonous models, in which tumors arise in their natural tissue environment after viral activation of oncogenic Kras, faithfully recapitulate the anatomy and evolution of human disease. When the investigators treated mice bearing Kras G12C tumors with sotorasib, the response was rapid and robust. Micro-computed tomography scans showed aeration returning to compressed lung tissue, and histological analysis confirmed widespread tumor regression. But the response was never complete. Even after two weeks of treatment, residual disease persisted, and it was this residual population that held the clues to what would come next.

Single-cell RNA sequencing of the residual tumors revealed something unexpected. Rather than resembling the aggressive adenocarcinoma cells that dominated before treatment, the surviving cells had shifted toward a transcriptional program resembling alveolar epithelial cells, the specialized gas-exchange cells of the lung. Markers such as HOPX and surfactant proteins became prominent. This finding aligns with a growing body of evidence that alveolar differentiation itself can blunt dependence on KRAS signaling, suggesting that the drug pushes tumors into a state where the oncogene matters less. The residual disease was not simply a smaller version of the original tumor; it was a fundamentally different cellular entity, poised at a lineage crossroads.

What happened under continued treatment was equally revealing. With sustained sotorasib administration, the researchers invariably observed genetic amplification of the Kras oncogene as the dominant resistance mechanism. Using advanced genomic tools, including whole-genome sequencing and computational reconstruction of amplification architecture, the team found that resistant tumors had accumulated extra copies of the mutant Kras allele, in some cases organized on circular extrachromosomal DNA, a notoriously dynamic form of oncogene amplification. Some tumors also amplified Myc or Mycn. This is a classic oncogene-centric escape: the cancer simply makes more of the drug target, overwhelming the inhibitor. In these tumors, MAPK pathway activity, measured by phosphorylated ERK staining, remained evident, confirming that KRAS signaling had been restored.

But oncogene amplification is only one route to resistance. The more provocative question the study addressed is whether tumors can escape KRAS dependence altogether by changing who they are. Histologic transformation, in which an adenocarcinoma converts to a squamous cell carcinoma or even small-cell lung cancer under the pressure of therapy, is a documented phenomenon in patients treated with EGFR and ALK inhibitors. The team used functional CRISPR approaches in their mouse models to deliberately promote squamous lineage transformation and ask whether this change in cellular identity could render tumors indifferent to KRAS inhibition.

The answer, established through a series of elegant experiments, was a clear yes. In alveolar organoid cultures derived from Kras-mutant, p53-deficient lung tissue, forced expression of the transcription factor ΔNp63 was sufficient to reprogram the adenocarcinoma cells into a squamous state. These reprogrammed organoids became strikingly insensitive to KRAS inhibitors, surviving drug concentrations that killed their untransformed counterparts. Critically, the squamous organoids did not show reactivation of KRAS or MAPK signaling when treated. Their resistance was not about reactivating the oncogene; it was about no longer needing it. The drug still hit its target, but the target no longer mattered to the cell’s survival.

In living animals, the team identified the genetic conditions that poise tumors for this fate. Loss of Nkx2-1, the master transcription factor that maintains lung adenocarcinoma identity, facilitated squamous transformation in autochthonous tumors. Ectopic expression of Sox2, the lineage-defining transcription factor of squamous lung cancer, cooperated with Nkx2-1 loss to drive adenosquamous tumors, mixed lesions containing both adenocarcinomatous and squamous components. When mice bearing these transformed tumors were treated with sotorasib for extended periods, the squamous compartments persisted and progressed while showing no evidence of KRAS or MAPK reactivation. Lineage transcription factors, the study concludes, can mediate genuine KRAS independence, a mechanism fundamentally distinct from the amplification-driven resistance seen in adenocarcinomas that retain their identity.

The mechanistic logic of this transformation is rooted in developmental biology. NKX2-1 acts as a guardian of alveolar and pulmonary fate, and its loss releases tumor cells from that commitment, allowing alternative lineage programs to take over. ΔNp63, the dominant-negative isoform of the p53 family member p63, is the molecular switch for stratified epithelial identity, essential for the proliferative potential of basal cells in squamous epithelia. SOX2, meanwhile, has been shown in prior work to be the determining oncogenic switch that promotes lung squamous carcinoma from multiple cells of origin. The new study ties these threads together into a coherent model: the balance between NKX2-1 and factors such as ΔNp63 and SOX2 governs whether a KRAS-mutant tumor remains addicted to its driver or can be reprogrammed into a state where the driver is dispensable.

The clinical implications are substantial. KRAS G12C inhibitors are now approved therapies, but clinical responses are incomplete and resistance is nearly universal, with documented mechanisms including new KRAS mutations, bypass signaling through EGFR and other receptors, and epithelial-to-mesenchymal transition. The mouse models in this study mirror that reality: initial responses were rapid but partial, and residual disease consistently evolved under drug pressure. If a subset of human tumors can achieve resistance through lineage plasticity rather than target reactivation, then combination strategies aimed solely at suppressing MAPK signaling will fail for those patients. Monitoring for lineage markers, such as NKX2-1 loss, ΔNp63 or SOX2 emergence, could identify patients whose tumors are drifting toward KRAS independence before overt progression, and biopsy of resistant lesions may need to look at histology as closely as genomics.

There is also a broader lesson for targeted therapy across oncology. The study echoes patterns seen in EGFR-mutant lung cancer, where squamous and small-cell transformation accompany resistance to osimertinib, often in tumors with RB1 and TP53 alterations. In those contexts too, the transformed tumors frequently lose dependence on the original driver. What this new work adds is a mechanistic, causally tested framework in mouse models: specific transcription factors are sufficient to confer drug resistance by rewriting cellular identity, and the resulting state is stable and heritable. Therapies that target the lineage machinery itself, or that prevent the plastic transition in the first place, may be needed alongside KRAS inhibitors to make responses durable. As KRAS drugs become a cornerstone of lung cancer treatment, this study makes clear that the battle against resistance will be fought not only over the oncogene, but over the very identity of the tumor cell.

Subject of Research: Lineage plasticity and transcription factor-driven squamous transformation as mechanisms of resistance to KRAS inhibitors in mouse models of non-small-cell lung cancer

Article Title: Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance

Article References: Mathey-Andrews, N., Rodriguez, C. L., Shui, B., Patriotis, A. L., Rideout, W. M., III, Chen, V. Z., Murazzi, I., Ghazi, P., Cornwall-Brady, M. R., Liu, M., Heileman, M. G., Trakala, M., Concepcion-Crisol, C. P., Yang, D., & Jacks, T. (2026). Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance. Nature Genetics. https://doi.org/10.1038/s41588-026-02768-8

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02768-8

Keywords: KRAS inhibitors, lung adenocarcinoma, lineage plasticity, squamous transformation, NKX2-1, SOX2, DeltaNp63, drug resistance, genetically engineered mouse models, targeted therapy, MAPK signaling, histologic transformation

The research, led by Zihao Deng, Lifang He, and colleagues under corresponding author Yukun Cui at the Cancer Hospital of Shantou University Medical College, tackles a phenomenon known as lineage plasticity. This is the capacity of cancer cells to shed their original identity and adopt alternative cell states when pressured by therapy, a behavior increasingly recognized as a major driver of treatment resistance in prostate cancer and other tumors. In the androgen receptor-low or androgen receptor-null state, prostate cancer cells build extensive epigenetic barriers: their chromatin, the packaged form of DNA inside the nucleus, becomes inaccessible, and the three-dimensional architecture of the genome locks into a repressive topology that keeps the androgen receptor gene and its regulatory elements silenced. How that locking-in happens, and whether it can be reversed, has remained poorly understood.

KIF11, also known as kinesin family member 11, is best known as a mitotic kinesin, a motor protein that drives spindle assembly during cell division and has long been pursued as a chemotherapy target. Existing KIF11 inhibitors tend to work at cytotoxic doses that halt division in any rapidly proliferating cell. The Shantou team took a different angle. Combining public transcriptomic and epigenomic datasets with their own RNA sequencing, ATAC-seq chromatin accessibility profiling, RNA interference, low-dose pharmacological inhibition with the KIF11 inhibitor ispinesib, chromatin immunoprecipitation, chromosome conformation capture, DNA methylation assays, and reporter and therapeutic-response experiments, they asked what happens to prostate cancer cells when KIF11 activity is reduced gently rather than destroyed completely.

The answer surprised them. In androgen receptor-low and androgen receptor-null prostate cancer models, including PC3 and DU145 cells, either RNAi-mediated depletion or low-dose pharmacological inhibition of KIF11 activated androgen receptor-associated transcriptional programs. The cells began, in effect, to remember who they were supposed to be. Chromatin accessibility increased at androgen receptor regulatory regions, and the team measured higher occupancy of FOXA1 and GRHL2, two pioneering transcription factors that act as gatekeepers of the androgen receptor enhancer, at that key regulatory element. At the same time, the co-activator EP300 and the transcription elongation factor SUPT5H showed increased occupancy at androgen receptor regulatory elements, signaling that the locus was not merely open but actively engaged in productive transcription.

The mechanism went deeper than transcription factor recruitment. Using chromosome conformation capture techniques, the researchers showed that KIF11 inhibition reduced DNA methylation at CTCF motifs, the DNA sequences recognized by the CCCTC-binding factor, an architectural protein that anchors loops in the genome. With methylation lifted, CTCF occupancy rose, and the physical communication between enhancers and the androgen receptor promoter strengthened. In other words, KIF11 inhibition did not simply sprinkle activating marks on the genome; it rebuilt the three-dimensional wiring of the androgen receptor locus, constructing enhancer-promoter loops that bring distant regulatory elements into direct contact with the gene they control.

That topological resetting proved remarkably stable. Once the enhancer-promoter architecture was established, it locked in a sustained androgen receptor transcriptional program and created a feed-forward reinforcement circuit in which the reactivated pathway maintained its own expression. Functionally, this drove what the authors describe as a lineage return: androgen-insensitive, androgen receptor-low or null prostate cancer cells transitioned back into an androgen receptor-responsive transcriptional state. The change was not cosmetic. With the androgen receptor machinery restored, the cells regained the very dependency that antiandrogen drugs exploit.

The therapeutic consequences were tested across multiple model systems. In cell-line experiments, patient-derived castration-resistant prostate cancer organoids, and xenograft models in mice, low-dose KIF11 inhibition combined with enzalutamide or apalutamide produced robust growth suppression in tumors that would normally ignore these drugs. Crucially, the KIF11 inhibition used in these experiments was deliberately kept at low, non-cytotoxic doses, avoiding the broad toxicity that would come with hitting every dividing cell. The strategy is therefore conceptually distinct from conventional chemotherapy: rather than killing cancer cells directly, the treatment reprograms their regulatory architecture so that a second, well-tolerated class of drugs can work again.

The findings carry significant implications for how lineage plasticity-driven resistance might be overcome in the clinic. If a subset of patients with androgen receptor-low or null disease could be identified, perhaps through biopsy-based profiling of KIF11 levels, CTCF methylation status, or androgen receptor locus topology, they might become candidates for a re-sensitization strategy in which short-term KIF11 inhibition converts their tumors into androgen receptor-dependent ones before initiating or resuming antiandrogen therapy. The authors note that Y. Cui and Z. Deng have filed a patent application related to the findings, suggesting momentum toward translational development. At the same time, the work remains at the preclinical stage, and questions about dosing windows, patient selection, and safety in humans will need to be addressed in future studies.

Scientifically, the study adds an important dimension to a growing body of work showing that cancer is as much a disease of genome architecture as of genome sequence. The idea that inhibiting a mitotic motor protein could demethylate CTCF sites, reopen chromatin, reorganize enhancer-promoter loops, and ultimately restore a whole lineage identity illustrates how deeply intertwined cell division machinery, epigenetics, and three-dimensional genome organization really are. For patients with castration-resistant prostate cancer whose tumors have gone androgen-receptor silent, the research offers a conceptually elegant possibility: the door that cancer slammed shut can, with the right molecular key, be opened again, and the treatments already on the shelf may once more find their target.

Subject of Research: KIF11 inhibition as a lineage-remodeling strategy to restore androgen receptor signaling and antiandrogen sensitivity in castration-resistant prostate cancer

Article Title: KIF11 inhibition remodels lineage state and sensitizes castration-resistant prostate cancer to antiandrogen therapy via enhancer–promoter looping

Article References: Deng, Z., He, L., Li, J., She, S., Luo, X., Lin, J., Qi, Z., Zhuang, Y., Gao, X., Chi, Z., Xu, Z., Ji, Y., Liu, J., Lin, S. L., & Cui, Y. (2026). KIF11 inhibition remodels lineage state and sensitizes castration-resistant prostate cancer to antiandrogen therapy via enhancer–promoter looping. Molecular Cancer. https://doi.org/10.1186/s12943-026-02792-6

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02792-6

Keywords: KIF11, castration-resistant prostate cancer, androgen receptor, lineage plasticity, enhancer-promoter looping, CTCF, epigenetics, enzalutamide, apalutamide, FOXA1, patient-derived organoids, drug resistance